Decentralized panel event featured during J.P. Morgan; Fireside chat with Dr. David Fajgenbaum, author of “Chasing My Cure”
PALO ALTO, Calif.--(BUSINESS WIRE)--#digitaltrials--Medable Inc., the end-to-end platform for digitally enabled and data-driven clinical trials, today announced that Medable will host DCentralized, an evening at Hibernia Bank, featuring astute panelists discussing the state of decentralized clinical trials. Panelists include panel moderator Amir Kalali of CNS, Rasmus Hogreffe of Leo Pharma, Mads Dalsgaard of Lundbeck, Ritesh Patel of Ogilvy, and Dr. Michelle Longmire of Medable. The event kicks off with a Clemson vs. LSU watch party, followed by a panel discussion, and ending with a DJ dance party, featuring DJ cameos by Rasmus Hogreffe and Ritesh Patel. Doors open at 5:00 pm at Hibernia Bank, 1 Jones Street, SF.
Tuesday, January 14th, Dr. David Fajgenbaum, author of “Chasing My Cure” will join Dr. Michelle Longmire, CEO, and co-founder of Medable, in an open conversation, discussing Dr. Fajgenbaum’s heroic journey discovering a cure for Castleman’s disease. The event will be held from 5:30 pm - 8:00 pm at Covo SF, 981 Mission Street, SF.
Other events featuring Medable during J.P. Morgan include:
Dr. Michelle Longmire, CEO, and co-founder will present at the Digital Medicine and Medtech Showcase 2020, January 13, 2020, at the Parc 55 Hotel in San Francisco, California.
Dr. Longmire will also be speaking at the Phase2 and HealthX annual event, January 14, 2020, at the Monroe, 473 Broadway in San Francisco
Schedule a meeting with Medable at J.P. Morgan.
Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Medable is on a mission to get effective therapies to patients faster by dramatically reducing the time from therapeutic development to market realization with digital data capture and real-time analytics that remove the complexities of clinical research to dramatically reduce trial timelines. Medable is pioneering a new category of life science technologies that replace the stagnant and siloed data of traditional ePRO, eCOA, EDC, and eSource with an intelligent and unified end-to-end (E2E) platform for clinical trial execution. Our platform allows patients, healthcare providers, clinical research organizations and pharmaceutical sponsors to work together as a connected and empowered team in clinical trials.
For more information, visit www.medable.com and follow Medable on Twitter: @Medableinc
Letitia Rodley, VP Marketing